Digital Media Net - Your Gateway To Digital media Creation. News and information on Digital Video, VR, Animation, Visual Effects, Mac Based media. Post Production, CAD, Sound and Music
Categories: News

Biometric Identification and Cybersecurity Software Solutions Provider BIO-key Presents at DealFlow Discovery Investor Conference at 11:30am ET, Jan. 28 in Atlantic City, NJ

ATLANTIC CITY & HOLMDEL, NJ / ACCESS Newswire / January 13, 2026 / BIO-key® International, Inc. (NASDAQ:BKYI), a leading provider of biometric enabled Identity and Access Management SaaS solutions for phoneless, tokenless, passwordless, and phish-resistant authentication, will participate at the DealFlow Discovery Conference Wednesday and Thursday, January 28th and 29th at the Borgata hotel in Atlantic City, New Jersey. Institutional investors, family offices and high-net-worth investors are invited to attend at no cost.

BIO-key CEO Mike DePasquale will present on Wednesday at 11:30 am ET in Room 1 and will be available for 1-on-1 meetings throughout the event. BIO-key’s presentation details will be posted on DealFlow’s website in January.

Registration:

Click here: https://dealflowdiscoveryconference.com/registration/ to register for the Discovery Conference.

About The DealFlow Discovery (www.dealflowdiscoveryconference.com)

The DealFlow Discovery Conference is where high-growth companies come to be discovered. Formerly known as The Microcap Conference, the event has been expanded to include both publicly traded microcaps and qualified private companies across a variety of high-growth sectors.

Organized by DealFlow Events, the conference brings together hundreds of companies, investors, and dealmakers for two days of company presentations, expert discussions on raising capital, unlimited 1-on-1 meetings, interactive sessions and networking opportunities. The Discovery Conference delivers a high visibility platform for companies to showcase their value propositions to a broad base of prospective investors.

Keynote presentations and panel discussions led by renowned industry figures will provide insights on business, investing, entrepreneurial success, and other trends in US equity markets, from capital formation to regulatory updates, tailored to the public microcap and private market communities.

About BIO-key International, Inc. (www.BIO-key.com)

BIO-key is revolutionizing authentication and cybersecurity with biometric-centric, multi-factor identity and access management (IAM) software securing access for over forty million users. BIO-key allows customers to choose the right authentication factors for diverse use cases, including phoneless, tokenless, and passwordless biometric options. Its cloud-hosted or on-premise PortalGuard IAM solution provides cost-effective, easy-to-deploy, convenient, and secure access to computers, information, applications, and high-value transactions.

Engage with BIO-key:

LinkedIn – Corporate: https://www.linkedin.com/company/bio-key-international

X – Corporate: @BIOkeyIntl

X – Investors: @BIO_keyIR

StockTwits: BIO_keyIR

Investor Contacts:
William Jones, David Collins
Catalyst IR
BKYI@catalyst-ir.com or 212-924-9800

SOURCE: DealFlow Events

View the original press release on ACCESS Newswire

Staff

Recent Posts

The Inner Circle acknowledges Forest Young as a Pinnacle Professional Member Inner Circle of Excellence

BROOKLYN, N.Y., June 8, 2026 /PRNewswire/ -- Prominently featured in The Inner Circle, Forest Young…

8 hours ago

Intermountain Infrastructure Group Announces Northern Tier Fiber Route Now 70 Percent Complete, Targeted For Late 2026 Delivery

IIG's constructed, owned-and-operated northern corridor is attracting strong customer demand, with further expansion already under…

22 hours ago

Automatic First-Time Penalty Abatement Arrives in 2026 – Clear Start Tax Explains Who the IRS Now Forgives Without Asking

As of the 2025 filing season, the IRS is applying First-Time Abatement automatically - without…

22 hours ago

AGS Health(R) Launches InnovationWorks(TM) to Turn the Promise of Revenue Cycle AI and Automation into Outcomes That Matter to Providers

WASHINGTON, DC / ACCESS Newswire / June 8, 2026 / AGS Health®, a leading provider…

22 hours ago

GEN Announces First Patient Dosed in Phase II Clinical Trial of SUL-238 in Parkinson’s Disease

Proof-of-concept SHEPHERD study will assess SUL-238's effects on mitochondrial function in patients with Parkinson's disease.…

22 hours ago

Jerash Holdings to Present at the Planet MicroCap Las Vegas 2026 Investor Conference

FAIRFIELD, NJ / ACCESS Newswire / June 8, 2026 / Jerash Holdings (US), Inc. (Nasdaq:JRSH),…

22 hours ago